US20100041770A1 - Polymer-ceramic composite and method - Google Patents
Polymer-ceramic composite and method Download PDFInfo
- Publication number
- US20100041770A1 US20100041770A1 US12/447,959 US44795907A US2010041770A1 US 20100041770 A1 US20100041770 A1 US 20100041770A1 US 44795907 A US44795907 A US 44795907A US 2010041770 A1 US2010041770 A1 US 2010041770A1
- Authority
- US
- United States
- Prior art keywords
- composite material
- polymer phase
- poly
- alpha
- mixing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L27/46—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L27/446—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with other specific inorganic fillers other than those covered by A61L27/443 or A61L27/46
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/12—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/20—Compounding polymers with additives, e.g. colouring
- C08J3/205—Compounding polymers with additives, e.g. colouring in the presence of a continuous liquid phase
- C08J3/21—Compounding polymers with additives, e.g. colouring in the presence of a continuous liquid phase the polymer being premixed with a liquid phase
- C08J3/212—Compounding polymers with additives, e.g. colouring in the presence of a continuous liquid phase the polymer being premixed with a liquid phase and solid additives
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K3/00—Use of inorganic substances as compounding ingredients
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K3/00—Use of inorganic substances as compounding ingredients
- C08K3/01—Use of inorganic substances as compounding ingredients characterized by their specific function
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L67/00—Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2367/00—Characterised by the use of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Derivatives of such polymers
- C08J2367/04—Polyesters derived from hydroxy carboxylic acids, e.g. lactones
Definitions
- the present invention relates to composite materials of ceramic and polymer.
- the invention relates to bone replacement or void filler.
- bones need repair, such as filling voids.
- bones or portions of bones are replaced with artificial materials. It is desirable to use a material that is easy to put in place, and a material with desirable mechanical properties such as high strength and toughness.
- FIG. 1 is an example of a method of forming a composite material according to an embodiment of the invention.
- FIG. 2 is an example of a composite material in place according to an embodiment of the invention.
- FIG. 3 is an example of a delivery system and method according to an embodiment of the invention.
- FIG. 4 is test data from an example embodiment of a cured composite material according to an embodiment of the invention.
- FIG. 5 is test data from an example embodiment of drug release over time according to an embodiment of the invention.
- FIG. 6 is test data from an example embodiment of composite material degradation over time according to an embodiment of the invention.
- FIG. 7 is test data from another example embodiment of drug release over time according to an embodiment of the invention.
- FIG. 8 is test data from another example embodiment of composite material degradation over time according to an embodiment of the invention.
- FIG. 9 is test data from another example embodiment of drug release over time according to an embodiment of the invention.
- FIG. 1 shows an example method of forming a composite material.
- a polymer phase of the composite is prepared by mixing a polymer with a solvent.
- the example illustrated in operation 100 mixes a poly(alpha-hydroxy ester) with a solvent to keep the polymer in a non-solid state.
- non-solid includes a liquid, a viscous fluid, a gel, etc.
- having the polymer phase in a non-solid state facilitates a number of application methods for the composite material, including spreading, ejecting from a tube or syringe, etc.
- a poly(alpha-hydroxy ester) is different from other polymers in that a poly(alpha-hydroxy ester) provides a polymer that can be hydrolyzed inside a patient with the hydrolyzed components being absorbed into the body.
- Poly(alpha-hydroxy esters) are also well researched in medical device technologies. As a result, the properties of poly(alpha-hydroxy esters) are better known than properties of other polymers.
- the use of poly(alpha-hydroxy esters) in patients is approved by many governing bodies such as the United States Food and Drug Administration.
- the polymer phase includes a copolymer where one or more portions are poly(alpha-hydroxy esters).
- One example includes poly(lactide-co-glycolide) and another example includes poly(lactide-co-caprolactone).
- Other copolymers where one or more portions are poly(alpha-hydroxy esters) include polyethylene glycol (PEG) as a component along with one or more poly(alpha-hydroxy esters) such as those listed above.
- Selection of an appropriate polymer phase includes identification of desired properties such as mechanical strength, adhesion to the ceramic phase, biocompatibility, bioabsorption rate, solubility in a particular solvent, etc.
- a solvent is used with the poly(alpha-hydroxy esters) to keep the polymer phase in a non-solid state.
- solvents are available within the scope of the invention.
- Example solvents are polar aprotic solvents that include, but are not limited to, n-methyl-2-pyrrolidone (NMP), 2-pyrrolidone and dimethyl sulfoxide (DMSO).
- NMP n-methyl-2-pyrrolidone
- DMSO dimethyl sulfoxide
- Other acceptable solvents exhibit properties such as acceptable solubility of the polymer in the solvent, non-toxicity to a patient, and solubility of the solvent in water.
- Organic solvents such as the example solvents listed above also provide good solubility for pharmaceutical agents, such as statins that may be added to the composite material in selected embodiments described in more detail below.
- non-solid composite such as a mixture, suspension, slurry, etc.
- non-solid composites include both flowable materials and moldable materials.
- features of a non-solid state includes easy application and workability of the non-solid composite.
- a non-solid composite is pushed out of a syringe or otherwise extruded from a reservoir. Sculpting a desired shape of a composite is also possible depending on the viscosity and/or consistency of the non-solid composite.
- Materials in the bioabsorbable ceramic phase include, but are not limited to various phases, physical states, and chemistries of calcium phosphate and/or calcium sulfate.
- a calcium phosphate cement composition is used as the bioabsorbable ceramic material.
- calcium phosphates and calcium sulfates include, but are not limited to: crystalline calcium phosphates or calcium sulfates; dicalcium phosphate anhydrous-CaHPO 4 ; dicalcium phosphate dihydrate-CaHPO 4 .2H 2 O; ⁇ -tricalcium phosphate-Ca 3 (PO 4 ) 2 ; ⁇ ′-tricalcium phosphate-Ca 3 (PO 4 ) 2 ; ⁇ -tricalcium phosphate-Ca 3 (PO 4 ) 2 ; hydroxyapatite-Ca 5 (PO 4 ) 3 OH, or Ca 10 (PO 4 ) 6 (OH) 2 ; tetracalcium phosphate-Ca 4 (PO 4 ) 2 O; octacalcium phosphate-Ca 8 H 2 (PO 4 ) 6 .5H 2 O; calcium sulfate anhydrous-CaSO 4 ; ⁇ -calcium sulfate hemihydrate
- the non-solid composite is placed in an aqueous environment.
- a patient is having a bone repaired or replaced.
- a void or other defect for example, can be filled with the non-solid composite.
- the environment inside a patient contains sufficient water to be included in an aqueous environment in the present disclosure.
- the biological fluids in a patient that surrounds the non-solid composite drives out the solvent from the polymer.
- the polymer then precipitates or otherwise hardens within the composite material to form a solid material.
- the solvent is easily absorbed into the body as it is diffused out.
- FIG. 2 One example of a resulting solid composite structure is shown in FIG. 2 .
- a first existing bone portion 210 and a second existing bone portion 220 are shown with a solid composite structure 230 .
- the composite structure 230 includes a polymer phase 232 and a bioabsorbable ceramic phase 234 .
- the bioabsorbable ceramic phase 234 is dispersed within the polymer phase 232 matrix.
- the composite structure 230 is applied to a desired location, such as between the first existing bone portion 210 and a second existing bone portion 220 in a non-solid state. Once in place, the composite structure 230 is cured as water diffuses into the structure as shown by arrow 240 , and the solvent diffuses out of the structure as shown by arrow 242 .
- a resulting composite structure formed from poly (DL-lactide) and calcium phosphate cement in a ratio of 1:3 respectively provided a compressive strength of 3-5 MPa after curing for 24 hours at approximately 37 degrees C.
- one method includes degrading the composite structure 230 over time to be bioabsorbed into the body of the patient while the composite structure 230 is replaced by new bone growth.
- a bioabsorption rate of the ceramic phase is compared to a bioabsorption rate of the polymer phase.
- the bioabsorption rate of the polymer phase is controlled by varying a molecular weight of the polymer phase. Other methods of controlling the bioabsorption rate of the polymer phase are also within the scope of the invention.
- a bioabsorption rate of the ceramic phase is also controlled.
- the respective rates of bioabsorption are controlled within the composite to achieve a desired bone growth mechanism.
- One method includes adjusting the bioabsorption rate of the polymer phase to approximately match the bioabsorption rate of the ceramic phase. Matching rates of bioabsorption reduce the possibility of leaving behind a pocked or holed structure where one of the phases has been absorbed faster than the other. In other methods, a pocked or holed structure is desired to provide nucleation sites for new bone growth.
- a hydrophilic agent is included in the polymer phase of the composite to adjust the respective rates of bioabsorption as noted above.
- the hydrophilic agent includes a hydrophilic oligomer or polymer. Hydrophilic agents, including oligomers or polymers, etc. are absorbed more readily than other components in the composite material, leaving pores behind in the composite.
- hydrophilic agents examples include polyvinyl alcohol (PVA), polyvinyl pyrrolidone (PVP), polyethylene glycol (PEG), and polyethylene oxide (PEO), etc.
- PVA polyvinyl alcohol
- PVP polyvinyl pyrrolidone
- PEG polyethylene glycol
- PEO polyethylene oxide
- hydrophilic agents include oligosacchrides, polysacchrides and their derivatives, such as dextran, alginate, hyaluronate, carboxymethyl cellulose, hydroxypropyl methyl cellulose or other cellulose derivatives.
- pores are desirable, and used to adjust parameters such as available nucleation sites for replacement bone growth and exposed surface area, which is related to rate of release of other included elements such as pharmaceutical agent (discussed in more detail below).
- hydrophilic polymers are described, other materials that are included in the composite material to control rate of porosity are within the scope of the invention.
- hydrophilic polymers can be included in the composite material by a number of possible mechanisms including, but not limited to, copolymerization, physical blending, etc.
- a pharmaceutical agent 250 is included within the composite structure 230 .
- a pharmaceutical agent 250 includes a bone growth promoting agent.
- a statin such as simvastatin is an example of a pharmaceutical agent that has been shown to promote bone growth.
- a hydrophobic pharmaceutical agent such as a statin is dissolved in an organic solvent such as n-methyl-2-pyrrolidone (NMP), 2-pyrrolidone or dimethyl sulfoxide (DMSO) as discussed above.
- NMP n-methyl-2-pyrrolidone
- DMSO dimethyl sulfoxide
- An advantage of such a solvent/pharmaceutical agent combination includes a more reproducible drug release profile as the composite material degrades, due to more even distribution of the pharmaceutical agent within the composite material. In selected embodiments, such a property is desirable to minimize rapid release of the pharmaceutical agent and to prolong the release profile.
- bone growth promoting agents that may be included within the composite structure 230 include, but are not limited to, proteins or peptides that are related to bone formation, healing and repair.
- proteins include bone morphogenic proteins (BMPs), osteogenic proteins (OP), transforming growth factors (TGF), insulin-like growth factor (IGF), platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF).
- compositions 230 include antibiotics, analgesics, and cancer drugs, or a combination of any agents listed above.
- a pharmaceutical agent 250 or agents are contained within the polymer phase 232 of the composite structure 230 , although the invention is not so limited.
- Other examples of composite structures 230 include pharmaceutical agents in the ceramic phase, or both the polymer and the ceramic phase.
- the pharmaceutical agent 250 diffuses out of the composite structure 230 and into surrounding tissue or into adjacent bone over time as shown by arrows 252 .
- the pharmaceutical agent 250 is released as the composite structure 230 degrades.
- a ratio of polymer phase to ceramic phase controls a rate of release of the pharmaceutical agent 250 .
- FIG. 3 illustrates one example of a delivery system 300 according to an embodiment of the invention.
- a storage chamber 310 is illustrated with a quantity of non-solid composite material 320 as described in embodiments above contained within the storage chamber 310 .
- the delivery system 300 includes a syringe, although the invention is not so limited.
- a plunger 312 is pressed to dispense the non-solid composite material 320 from the storage chamber 310 out through a nozzle 314 .
- FIG. 3 illustrates using the delivery system 300 to fill a void 332 in a bone surface 330 such as a skull for example.
- a quantity 322 of the non-solid composite material 320 fills in the void 332 while in the non-solid state.
- biological fluids from the patient tissue drives out the solvent within the polymer phase of the non-solid composite material 320 and cures the composite into a solid.
- the non-solid composite material 320 is stored within the storage chamber 310 in the non-solid state until needed. Upon application, the composite material then cures. In other examples, the non-solid composite material 320 is prepared just before a procedure from components such as polymer, solvent, and ceramic. The non-solid composite material 320 is then applied and cured in place.
- a composite material is easily applied to a portion of bone in need of filling or reinforcement, etc.
- the composite material provides good mechanical properties such as compressive strength upon curing.
- Selected materials and methods as described are further bioabsorbable with absorption rates that are controllable to provide a desired effect.
- a pharmaceutical agent further provides benefits such as bone growth and formation, infection resistance, pain management, etc.
- FIGS. 4-9 show selected test data from example embodiments.
- the materials, such as polymers, ceramic phases, and solvents shown are illustrated as examples only.
- the specific preparation and test methods are shown as examples only.
- the scope of the invention includes any other materials or combination and methods as determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled.
- FIG. 4 illustrates X-ray diffraction spectra of the PLGA/calcium phosphate cement in phosphate buffered saline (PBS) (pH 7.4) at 37° C. for 1 week.
- the test sample was prepared and evaluated as follows.
- NMP phosphate buffered saline
- 3 g calcium phosphate cement powder was then mixed with 6 g of PLGA-NMP to form a paste-like mixture, which was injected through a 3 mL oral syringe with an opening of 3 mm into phosphate buffered saline (pH 7.4) at 37° C. for 1 week.
- the mixture started to harden in contact with PBS.
- calcium phosphate cement cured into hydroxyapatite with trace calcium carbonate ( FIG. 4 ), which resembles the bone mineral phase.
- FIG. 6 illustrates degradation of the same test sample.
- FIG. 8 illustrates degradation of the same test sample.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Composite Materials (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Vascular Medicine (AREA)
- Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Materials For Medical Uses (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Biological Depolymerization Polymers (AREA)
- Prostheses (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
- Curing Cements, Concrete, And Artificial Stone (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/447,959 US20100041770A1 (en) | 2006-10-31 | 2007-10-31 | Polymer-ceramic composite and method |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85590406P | 2006-10-31 | 2006-10-31 | |
PCT/US2007/023014 WO2008054794A2 (en) | 2006-10-31 | 2007-10-31 | Polymer-ceramic composite and method |
US12/447,959 US20100041770A1 (en) | 2006-10-31 | 2007-10-31 | Polymer-ceramic composite and method |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100041770A1 true US20100041770A1 (en) | 2010-02-18 |
Family
ID=39344908
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/447,959 Abandoned US20100041770A1 (en) | 2006-10-31 | 2007-10-31 | Polymer-ceramic composite and method |
Country Status (11)
Country | Link |
---|---|
US (1) | US20100041770A1 (ja) |
EP (1) | EP2086604A2 (ja) |
JP (1) | JP2010508071A (ja) |
KR (1) | KR20090091710A (ja) |
CN (1) | CN101600462A (ja) |
AU (1) | AU2007314268A1 (ja) |
BR (1) | BRPI0718068A2 (ja) |
CA (1) | CA2668265A1 (ja) |
CO (1) | CO6190540A2 (ja) |
WO (1) | WO2008054794A2 (ja) |
ZA (1) | ZA200903689B (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8114427B2 (en) | 1998-09-11 | 2012-02-14 | Gerhard Schmidmaier | Biologically active implants |
US10064892B2 (en) | 2013-07-18 | 2018-09-04 | Kuros Biosciences B.V. | Method for producing an osteoinductive calcium phosphate and products thus obtained |
US10682442B2 (en) | 2014-04-04 | 2020-06-16 | University Of Kentucky Research Foundation | Small molecule drug release from in situ forming degradable scaffolds incorporating hydrogels and bioceramic microparticles |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100226956A1 (en) * | 2009-03-06 | 2010-09-09 | Per Kjellin | Production of moldable bone substitute |
CN102858278B (zh) * | 2010-04-29 | 2016-08-17 | 华沙整形外科股份有限公司 | 可流动陶瓷胶泥 |
EP3190089A4 (en) | 2014-09-01 | 2018-06-20 | Kyushu University, National University Corporation | Method for manufacturing product inorganic compound and product inorganic compound |
WO2016140626A1 (en) * | 2015-03-04 | 2016-09-09 | Agency For Science, Technology And Research | Composite material for drug delivery |
EP3954402A4 (en) * | 2019-08-31 | 2023-01-11 | Shenzhen Corliber Scientific Co., Ltd. | PLASTIC ARTIFICIAL BONE COMPOSITE MATERIAL AND METHOD OF PREPARING THE SAME |
CN111110929B (zh) * | 2020-02-15 | 2020-12-22 | 深圳脉动医学技术有限公司 | 一种高生物安全性心脏支架及其制造方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030104029A1 (en) * | 2001-12-04 | 2003-06-05 | Inion Ltd. | Resorbable polymer composition, implant and method of making implant |
US20040230309A1 (en) * | 2003-02-14 | 2004-11-18 | Depuy Spine, Inc. | In-situ formed intervertebral fusion device and method |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0302026D0 (en) * | 2003-01-29 | 2003-02-26 | Biocomposites Ltd | Bioabsorbable implant |
WO2006015316A1 (en) * | 2004-07-30 | 2006-02-09 | University Of Nebraska | Bioresorbable composites and method of formation thereof |
-
2007
- 2007-10-31 WO PCT/US2007/023014 patent/WO2008054794A2/en active Application Filing
- 2007-10-31 CA CA002668265A patent/CA2668265A1/en not_active Abandoned
- 2007-10-31 AU AU2007314268A patent/AU2007314268A1/en not_active Abandoned
- 2007-10-31 KR KR1020097009947A patent/KR20090091710A/ko not_active Application Discontinuation
- 2007-10-31 EP EP07867330A patent/EP2086604A2/en not_active Withdrawn
- 2007-10-31 BR BRPI0718068-3A2A patent/BRPI0718068A2/pt not_active IP Right Cessation
- 2007-10-31 CN CNA2007800445770A patent/CN101600462A/zh active Pending
- 2007-10-31 US US12/447,959 patent/US20100041770A1/en not_active Abandoned
- 2007-10-31 JP JP2009534709A patent/JP2010508071A/ja not_active Withdrawn
-
2009
- 2009-05-27 ZA ZA200903689A patent/ZA200903689B/xx unknown
- 2009-05-28 CO CO09054994A patent/CO6190540A2/es not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030104029A1 (en) * | 2001-12-04 | 2003-06-05 | Inion Ltd. | Resorbable polymer composition, implant and method of making implant |
US20040230309A1 (en) * | 2003-02-14 | 2004-11-18 | Depuy Spine, Inc. | In-situ formed intervertebral fusion device and method |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8114427B2 (en) | 1998-09-11 | 2012-02-14 | Gerhard Schmidmaier | Biologically active implants |
US10646622B2 (en) | 1998-09-11 | 2020-05-12 | Gerhard Schmidmaier | Biologically active implants |
US10064892B2 (en) | 2013-07-18 | 2018-09-04 | Kuros Biosciences B.V. | Method for producing an osteoinductive calcium phosphate and products thus obtained |
US10561683B2 (en) | 2013-07-18 | 2020-02-18 | Kuros Biosciences B.V. | Method for producing an osteoinductive calcium phosphate and products thus obtained |
US11147836B2 (en) | 2013-07-18 | 2021-10-19 | Kuros Biosciences B.V. | Method for producing an osteoinductive calcium phosphate and products thus obtained |
US10682442B2 (en) | 2014-04-04 | 2020-06-16 | University Of Kentucky Research Foundation | Small molecule drug release from in situ forming degradable scaffolds incorporating hydrogels and bioceramic microparticles |
Also Published As
Publication number | Publication date |
---|---|
CA2668265A1 (en) | 2008-05-08 |
ZA200903689B (en) | 2010-08-25 |
EP2086604A2 (en) | 2009-08-12 |
WO2008054794A2 (en) | 2008-05-08 |
JP2010508071A (ja) | 2010-03-18 |
BRPI0718068A2 (pt) | 2013-10-29 |
WO2008054794A3 (en) | 2008-09-18 |
CN101600462A (zh) | 2009-12-09 |
KR20090091710A (ko) | 2009-08-28 |
CO6190540A2 (es) | 2010-08-19 |
AU2007314268A1 (en) | 2008-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20100041770A1 (en) | Polymer-ceramic composite and method | |
JP4644252B2 (ja) | インサイチュー硬化ペースト、その製造および使用 | |
US9180224B2 (en) | Composite bone graft substitute cement and articles produced therefrom | |
US8551514B2 (en) | Gel suitable for implantation and delivery system | |
JP5744104B2 (ja) | 生体再吸収性ポリマーマトリックス、ならびにその作製および使用方法 | |
JP5406713B2 (ja) | 分解安定化ポリマーを含む生体材料 | |
US8025903B2 (en) | Composite bone graft substitute cement and articles produced therefrom | |
AU2012376506B2 (en) | Bone Putty | |
US10682442B2 (en) | Small molecule drug release from in situ forming degradable scaffolds incorporating hydrogels and bioceramic microparticles | |
WO2012170417A2 (en) | Methods and compositions to enhance bone growth comprising a statin | |
JP2010046249A (ja) | 硬組織補填材 | |
WO2013163705A1 (pt) | Material injetável biorreabsorvível bioativo e processos de preparação de material injetável biorreabsorvível bioativo | |
Moussi et al. | Injectable macromolecule-based calcium phosphate bone substitutes | |
KR20210109335A (ko) | 골 이식용 생체재료 | |
CN118045230A (zh) | 人造骨膜 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SYNTHES (U.S.A.),PENNSYLVANIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LIU, XINYIN;FULMER, MARK THOMAS;GRUSKIN, ELLIOTT;REEL/FRAME:023120/0758 Effective date: 20080326 Owner name: SYNTHES GMBH,SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LEPRE, MILVIA;REEL/FRAME:023120/0762 Effective date: 20080326 |
|
AS | Assignment |
Owner name: SYNTHES (U.S.A.),PENNSYLVANIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SYNTHES GMBH;REEL/FRAME:023124/0071 Effective date: 20080328 Owner name: SYNTHES GMBH,SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SYNTHES (U.S.A.);REEL/FRAME:023124/0078 Effective date: 20080328 Owner name: SYNTHES USA, LLC,PENNSYLVANIA Free format text: CHANGE OF NAME;ASSIGNOR:SYNTHES (U.S.A.);REEL/FRAME:023124/0242 Effective date: 20081223 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: HAND INNOVATIONS LLC, FLORIDA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DEPUY SPINE, LLC;REEL/FRAME:030359/0001 Effective date: 20121230 Owner name: DEPUY SYNTHES PRODUCTS, LLC, MASSACHUSETTS Free format text: CHANGE OF NAME;ASSIGNOR:HAND INNOVATIONS LLC;REEL/FRAME:030359/0036 Effective date: 20121231 Owner name: DEPUY SPINE, LLC, MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SYNTHES USA, LLC;REEL/FRAME:030358/0945 Effective date: 20121230 |
|
AS | Assignment |
Owner name: HAND INNOVATIONS LLC, FLORIDA Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT APPL. NO. 13/486,591 PREVIOUSLY RECORDED AT REEL: 030359 FRAME: 0001. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNOR:DEPUY SPINE, LLC;REEL/FRAME:042621/0565 Effective date: 20121230 |
|
AS | Assignment |
Owner name: DEPUY SPINE, LLC, MASSACHUSETTS Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT APPLICATION NO. US 13/486,591 PREVIOUSLY RECORDED ON REEL 030358 FRAME 0945. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNOR:SYNTHES USA, LLC;REEL/FRAME:042687/0849 Effective date: 20121230 |